Sudden cardiac death in familial hypertrophic cardiomyopathy: Are 'benign' mutations really benign?

Pathology

Volumn 29, Issue 3, 1997, Pages 305-308

  Semsarian, C ^a   Yu, B ^a   Ryce, C ^a   Lawrence, C ^b   Washington, H ^c   Trent, R J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b NSW Institute of Forensic Medicine   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Benign; DNA; Familial hypertrophic cardiomyopathy; Malignant; Mutations; Sudden cardiac death; myosin heavy chain gene

Indexed keywords

DNA; MYOSIN HEAVY CHAIN; RESTRICTION ENDONUCLEASE;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; DNA DETERMINATION; FAMILIAL DISEASE; GENE MUTATION; HEART DEATH; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; MISSENSE MUTATION; OLIGONUCLEOTIDE PROBE; SUDDEN DEATH;

EID: 0030882952     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313029700169155     Document Type: Article

References (23)

1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-85.
2. Sasson Z, Rakowski H, Wigle ED. Hypertrophic cardiomyopathy. Cardiol Clinics 1988; 6: 233-88.
3. Maron BJ, Roberts WC, Edwards JE, McAllisler HA, Foley DD, Epstein SE. Sudden death in patients with hypertrophic cardiomyopathy: characterisation of 26 patients with functional limitation. Am J Cardiol 1978; 41: 803-10.
4. McKenna W, Deanfield J, Farugui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical electrocardiographic and haemodynamic features. Am J Cardiol 1981; 47: 532-8.
5. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7: 204-14.
6. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes - clinical, demographic and pathological profiles. JAMA 1996; 276: 199-204.
7. Gilman JK, Jalal S, Naccarelli GV. Predicting and preventing sudden death from cardiac causes. Circulation 1994; 90: 1083-92.
8. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981; 48: 252-7.
9. Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon RO, Bonow RO, Maron BJ, Epstein SE. Electrophysiological abnormalities in patients with hypertrophie cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989; 80: 1259-68.
10. Geisterfer-Lawrence AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophie cardiomyopathy: a beta-cardiac myosin heavy chain gene missense mutation. Cell 1990; 62: 999-1006.
11. Watkins H, MacRae C, Thierfelder L, Chou YH, Frennaux M, McKenna W, Seidman JG, Seidman CE. A disease locus for familial hypertrophie cardiomyopathy maps to chromosome 1q13. Nature Genet 1993; 3: 333-7.
12. Thierfelder L, MacRae C, Watkins H, Tomfohrde J, Williams M, McKenna W, Born K, Noeske G, Schlepper M, Bowcock A, Vosberg HP, Seidman CE, Seidman JG. A familial hypertrophie cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci USA 1993; 90: 6270-4.
13. Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna WJ, Maron BJ, Seidman JG, Seidman CE. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophie cardiomyopathy. Nature Genet 1995; 11: 434- 7.
14. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326: 1108-14.
15. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophie cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 1994; 89: 22-32.
16. Smart RV, Yu B, Le H, French JA, Richmond DR, Jeremy RW, Semsarian C, Cheung L, Ross DA, Trent RJ. DNA testing in familial hypertrophie cardiomyopathy: clinical and laboratory implications. Clin Genet 1996; 50: 169-75.
17. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase). Nucleic Acids Res 1992; 20: 1433.
18. Anan R, Greve G, Thierfelder L, Watkins HC, McKenna WJ, Solomon S, Vecchio C, Shono H, Nakao S, Tanaka H, Mares A, Towbin JA, Spirito P, Roberts R, Seidman JG, Seidman CE. Prognostic implications of novel β-cardiac myosin heavy chain gene mutations that cause familial hypertrophie cardiomyopathy. J Clin Invest 1994; 93: 280-5.
19. Marian AJ, Mares A, Kelly DP, Yu QT, Abchee AB, Hill R, Roberts R. Sudden cardiac death in hypertrophie cardiomyopathy: variability in phenotypic expression of β-myosin heavy chain mutations. Eur Heart J 1995; 16: 368-76.
20. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophie cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene: a 908 Leu-Val mutation and a 403 Arg-Gln mutation. Circulation 1992; 86: 345-52.
21. Marian AJ. Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers. Clin Cardiol 1995; 18: 189-98.
22. Lechin M, Quinones MA, Omran A, Hill R, Yu QT, Rakowski H, Wigle D, Liew CC, Sole M, Roberts R, Marian AJ. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophie cardiomyopathy. Circulation 1995; 92: 1808-12.
23. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin- converting enzyme polymorphism in hypertrophie cardiomyopathy and sudden cardiac death. Lancet 1993; 342: 1085-6.